These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF; AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835 [TBL] [Abstract][Full Text] [Related]
4. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
6. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. Rubio R; Serrano O; Carmena J; Asensi V; Echevarría S; Flores J; Ribera E; Zarraga M; Ocampo A; de la Fuente B; Sepúlveda MA; Mariño AI; Minguez C; Vicent R; Cartón JA; Moyano B; Esteban H; Mahillo B; Serrano L; González-García J; HIV Med; 2010 Oct; 11(9):545-53. PubMed ID: 20345884 [TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Le Tiec C; Barrail A; Goujard C; Taburet AM Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. Rusconi S; Giacomet V; Mameli C; Viganò A; Viganò O; Adorni F; Galli M; Zuccotti GV BMC Infect Dis; 2012 Aug; 12():179. PubMed ID: 22866946 [TBL] [Abstract][Full Text] [Related]
9. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K; Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026 [TBL] [Abstract][Full Text] [Related]
10. An update and review of antiretroviral therapy. Piacenti FJ Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488 [TBL] [Abstract][Full Text] [Related]
11. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Parienti JJ; Barrail-Tran A; Duval X; Nembot G; Descamps D; Vigan M; Vrijens B; Panhard X; Taburet AM; Mentré F; Goujard C Antimicrob Agents Chemother; 2013 May; 57(5):2265-71. PubMed ID: 23459496 [TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109 [TBL] [Abstract][Full Text] [Related]
13. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. Karlström O; Josephson F; Sönnerborg A J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658 [TBL] [Abstract][Full Text] [Related]
14. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J; J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of atazanavir in treatment-naive patients]. Moreno S; Hernández B; Dronda F Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611 [TBL] [Abstract][Full Text] [Related]
16. Fosamprenavir calcium plus ritonavir for HIV infection. Torres HA; Arduino RC Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501 [TBL] [Abstract][Full Text] [Related]
17. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M; Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834 [TBL] [Abstract][Full Text] [Related]
18. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D; Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869 [TBL] [Abstract][Full Text] [Related]
19. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
20. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F; Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]